http://ift.tt/eA8V8J
SAN DIEGO–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX) (“Ignyta”), a biotechnology company focused on precision medicine in oncology, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its common stock. In connection with this offering, Ignyta expects to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering
May 03, 2017 at 01:25AM
from
No comments:
Post a Comment